Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 'Won't find a more full pipeline for a company this size'
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(110)
•••
Comment by prophetoffactzon Dec 20, 2022 6:43pm
134 Views
Post# 35183481

RE:RE:RE:RE:'Won't find a more full pipeline for a company this size'

RE:RE:RE:RE:'Won't find a more full pipeline for a company this size'Biodexa will have a much stronger profile and much more credibility to pursue xB3 and Q-Sphera partnerships. I think this deal will accelerate xB3 and Q-Sphera. Being out of money, in debt, with a $10 million market cap trading on the TSX-V by appointment could be a big turn-off for many companies doing their DD on BTI. How stable is it? Biodexa's much stronger profile, asset base, and the potential multi-product xB3 option exercise in January as well as a potential deal with J&J on Q-Sphera in 2023 could greatly accelerate deal-flow. This merger positions BTI and Midatech to capitalize on it due to a number of factors. 2023 is a year of rapidly rising profile and accelerating dealfow, in my opinion.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities